Catumaxomab can effectively eliminate CD133+/EpCAM+CSCs in malignant ascites in patients with advanced ovarian cancer, gastric cancer and pancreatic cancer, which indicates that it has potential therapeutic applications in eradicating CSCs of epithelial cancers [66,67]. This evidence concerns the gene EPCAM and familial pancreatic carcinoma.